2020 American Transplant Congress
Is Azathioprine the Right Choice in De Novo Lung Transplantation?
*Purpose: The antiproliferative of choice in lung transplantation (LT) remains controversial. Limited data exists on azathioprine (AZA) dose reductions or the conversion of AZA to…2020 American Transplant Congress
Efficacy and Safety Outcomes by Donor Type in De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from Transform
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the efficacy and safety outcomes in de novo renal transplant (RTx) recipients receiving everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) versus mycophenolate with…2020 American Transplant Congress
Envarsus XR Use Can Benefit Serum Creatinine Levels in Vascularized Composite Allotransplantation Patients
*Purpose: Vascularized composite allotransplantation (VCA) is a life-enhancing (as opposed to life-saving) procedure. Therefore, minimizing adverse outcomes associated with chronic immunosuppression is vital to determining…2020 American Transplant Congress
HMGB1 Antagonizes the Immunosuppressive Effect of MSCs in AKI
*Purpose: Kidney ischemia reperfusion injury (IRI) is a common cause of acute kidney injury and an unavoidable consequence of kidney transplantation and still lacks specific…2020 American Transplant Congress
Autophagy-Lysosome Inhibitor Chloroquine Prevents CTLA-4 Degradation of T Cells and Attenuates Acute Rejection in Murine Skin and Heart Transplantation
*Purpose: The immune checkpoint cytotoxic T lymphocyte antigen-4 (CTLA-4), which was induced upon T cell activation but degraded quickly, has been targeted in the clinical…2020 American Transplant Congress
Belatacept Every Two Month Maintenance Dosing in Kidney Transplantation: A Randomized, Non-Inferiority Trial
Emory University School of Medicine, Atlanta, GA
*Purpose: Maintenance immunosuppression with belatacept following kidney transplantation results in a reduced risk of patient death and graft loss as compared to calcineurin inhibitors. However,…2020 American Transplant Congress
Mycophenolic Acid Exposure in Young, Middle Age and Older Stable Renal Transplant Recipients
*Purpose: Mycophenolic acid (MPA) is an essential drug in maintenance immunosuppressive regimens. In spite of increased kidney transplants in the elderly, limited pharmacokinetic investigations comparing…2020 American Transplant Congress
Kidney Transplant Results Comparing Two Formulations of Prolonged-Release Tacrolimus: Paired Study of Kidney Donors
*Purpose: Although the formulations of prolonged-release tacrolimus (Advagraf® and Envarsus®) are effective after kidney transplantation in terms of efficacy and safety, no paired analysis has…2020 American Transplant Congress
Integrated Multicohort Analysis of Transcriptome Profiles Identifies Blood Gene Signature to Distinguish Rejection from Infection in Patients with Solid Organ Transplants
School of Medicine, Stanford University, Stanford, CA
*Purpose: Allograft rejection and infection are now leading causes of morbidity and mortality in transplant recipients. Current diagnosis relies on nonspecific markers of graft injury,…2020 American Transplant Congress
Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression
*Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 138
- Next Page »